Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 139, Issue 3, Pages 657-663
Publisher
Wiley
Online
2016-03-21
DOI
10.1002/ijc.30099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
- (2015) Andreas Seeber et al. BMC CANCER
- Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: Tumor budding as oncotarget
- (2015) Oncotarget
- Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients
- (2014) Gunjan Srivastava et al. BMC CANCER
- Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences
- (2014) Olivier Gires et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Expression of EpCAMMFand EpCAMMTvariants in human carcinomas
- (2014) Dominic Fong et al. JOURNAL OF CLINICAL PATHOLOGY
- Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980
- (2013) C. Bosetti et al. ANNALS OF ONCOLOGY
- EpCAM proteolysis: new fragments with distinct functions?
- (2013) Ulrike Schnell et al. BIOSCIENCE REPORTS
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer
- (2013) Dominic Fong et al. HISTOPATHOLOGY
- Context-dependent adaption of EpCAM expression in early systemic esophageal cancer
- (2013) C Driemel et al. ONCOGENE
- Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
- (2012) M. Schmidt et al. ANNALS OF ONCOLOGY
- Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines
- (2012) Agnieszka Martowicz et al. BMC CANCER
- EpCAM regulates cell cycle progression via control of cyclin D1 expression
- (2012) A Chaves-Pérez et al. ONCOGENE
- EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
- (2011) M. Cioffi et al. CLINICAL CANCER RESEARCH
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
- (2011) K. Baumann et al. GYNECOLOGIC ONCOLOGY
- Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
- (2011) Marion G. Ott et al. INTERNATIONAL JOURNAL OF CANCER
- Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110
- (2011) Silke Petsch et al. mAbs
- EpCAM nuclear localization identifies aggressive Thyroid Cancer and is a marker for poor prognosis
- (2010) Ranju Ralhan et al. BMC CANCER
- Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM and ALDH1 in colorectal cancer
- (2010) A Lugli et al. BRITISH JOURNAL OF CANCER
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
- (2010) Norbert Marschner et al. UROLOGIA INTERNATIONALIS
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
- (2009) M. Schmidt et al. ANNALS OF ONCOLOGY
- EpCAM: Another Surface-to-Nucleus Missile
- (2009) Graham Carpenter et al. CANCER CELL
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
- (2009) Anthony L.A. Fields et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear signalling by tumour-associated antigen EpCAM
- (2009) Dorothea Maetzel et al. NATURE CELL BIOLOGY
- Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status
- (2008) Alessandro Lugli et al. MODERN PATHOLOGY
- Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials
- (2008) B. H. O'Neil et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started